Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update

Technical420 Site Search

Returned 42 result(s).

Pure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay Off

During the last month, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has reported several significant developments and is an opportunity that we are closely following. From forming strategic partnerships to purchasing cannabis biomass to launch a line of cannabis 2.0 products, Pure Extracts has been executing on…

MushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)

Over the past year there has been a significant increase in interest in companies that are focused on the psychedelic therapy market--a trend that we are following closely. Interest in these companies has been steadily rising in 2021, and we are focused on identifying businesses that have staying power. Tryp…

Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving Forward

If you have not been following Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), you may want to put the company on your radar after it closed a massive private placement. Last week, Field Trip reported to have closed a previously announced $95 million bought deal short form prospectus offering.…

Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that it has appointed Luke Hayes as its Chief Financial Officer. Mr. Hayes has been active in the life science…

Tryp Therapeutics Has Been Laser Focused On Executing On Its Business Plan Post Listing

Last month, we highlighted Tryp Therapeutics Inc. (CSE: TRYP) as a hyper-focussed play on the psychedelic biotech market and an opportunity that our readers need to be aware of. So far this year, Tryp has been executing on previously announced growth initiatives and the story has made substantial advancements. TRYP…

Numinus Wellness Is Making Major Headway On Its MDMA Trials

Last week, Numinus Wellness Inc. (TSXV: NUMI) reported a major development and we want to issue an update on the opportunity following this announcement. The company is focused on creating an ecosystem of health solutions that are centered around the development of evidence-based psychedelic-assisted psychotherapies. Last week, Numinus announced that…

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI") has begun the process of manufacturing the 200g non-GMP demonstration batch of psilocybin. This production step is one of…

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join…

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms…

Psychedelic Clinics Are A Major Vertical That Investors Need To Be Watching

The clinic opportunity is an exciting vertical of the psychedelic industry and is a market that our readers need to be aware of. Last year, the psychedelic clinic market recorded significant advancements, and this is a trend that is expected to continue. We believe the negative mental health effects that…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link